Cleveland Clinic Cole Eye Institute's landmark CATT study clarifies the relationship between gene risk indicators for age-related macular degeneration, and a person's response to treatments such as Avastin and Lucentis.
Cleveland Clinic Cole Eye Institute has named the Femtosecond Laser Technology as a top innovation in 2013. This technology, already popularly used for LASIK surgery, is found to have great results when used for cataract surgery. This offers patients with a bladeless option for cataract surgery that also increases incision accuracy, reduces surgery time, causes less inflammation, and offers more stability when implanting a new lens.
Cole Eye ophthalmologist Amy Babiuch, MD, discusses eye strain, a growing medical issue caused by constantly looking at technology such as computer or smart phone screens.
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
New study finds possible link between cognitive problems and damaged retinas
Cleveland Clinic retina specialist Dr. Rishi Singh comments on a new study that discusses a possible link in cognitive problems with retinal diseases in a recent WKYZ news interview.
Peter K. Kaiser, MD appointed Chaney Chair for Ophthalmic Research
Peter K. Kaiser, MD, has been appointed the Chaney Family Endowed Chair for Ophthalmology Research at Cole Eye Institute. A clinical trials specialist, he has chaired five major multicenter international retina trials. Dr. Kaiser serves on numerous study executive committees and was first to treat any patient with a modified small RNA-interfering molecule. Bruce and Virginia Chaney endowed the chair more than a decade ago in gratitude for their care at Cole Eye Institute. With the passing of the Chaneys, their son, with his wife and children, continue the family's support of vision research here.
Cleveland Clinic’s Cole Eye Institute received a $3 million gift from Barbara and A. Malachi Mixon III in recognition of the sight-saving care Mr. Mixon received at the Institute.
A new study shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis) for treating age-related macular degeneration (AMD). The study, led by Cleveland Clinic, was published online today in The New England Journal of Medicine (NEJM).
Premier surgeon announces the PS250 List of leading innovators in the field of premium IOL implant surgery
Ronald Krueger, MD was recently named to the PS250, a list of the nation's top surgeons in the field of premium IOL implant surgery. An intraocular lens (IOL) is an implanted lens in the eye, usually replacing the existing lens because it has been clouded over by a cataract, or as a form of refractive surgery to change the eye's optical power.